New hope for tough lung cancer: experimental drug takes on chemo in major trial
NCT ID NCT06382129
First seen Apr 19, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study compares a new drug, BL-B01D1, to a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that no longer responds to immunotherapy or platinum chemo. About 698 adults with a specific type of lung cancer (EGFR wild-type) will take part. The main goal is to see if BL-B01D1 helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.